Skip to Main Content

How much should drugs cost? To Dr. Peter Bach, the answer is almost always cheaper.

Bach is director of the Center for Health Policy and Outcomes at New York City’s Memorial Sloan Kettering Cancer Center. And, while there, he comes up with ideas and pushes for policies that would more closely align the price of drugs with their real value to patients in the health care system.


This week, Bach wrote an article for the New England Journal of Medicine in which he takes on the high cost of a new class of personalized cancer immunotherapy drugs known as CAR-T therapies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!